Life Sciences

  • June 29, 2026

    Asthma Drug Developer To Wind Down In Chancery Court

    A subsidiary of Rock Creek Advisors LLC created to administer the liquidation of an asthma drug developer to pay creditors notified Delaware's chancery court that the company turned to a wind-down after clinical trials came to a halt.

  • June 29, 2026

    Supreme Court Shuts Down 4 Patent Cases

    The U.S. Supreme Court turned down four petitions over patent law Monday, meaning it won't review questions related to prosecution laches, jury verdicts, patent eligibility and marking.

  • June 26, 2026

    4 Takeaways From The High Court's Monsanto Ruling

    The U.S. Supreme Court's highly anticipated ruling in favor of Monsanto over its blockbuster pesticide Roundup established that a pesticide's labeling must meet federal standards, ensuring that businesses don't have to comply with a variety of potentially conflicting state laws.

  • June 26, 2026

    PACER Fees Will Rise To Fund Cyber Defense Upgrades

    The federal judiciary announced Friday it will temporarily increase the fees for electronic access to court records to pay for a potential $800 million upgrade that will modernize and strengthen court records systems PACER and CM/ECF, an upgrade it previously said is needed to respond to escalating cyberattacks.

  • June 26, 2026

    Pfizer Beats Ex-Worker's Whistleblower Retaliation Suit

    Pfizer defeated a former employee's whistleblower retaliation suit Friday after a California federal judge ruled the "uncontroverted material facts" show the company would have fired him for "legitimate, independent reasons" even if he did engage in protected whistleblowing.

  • June 26, 2026

    Endoscopy Device Maker's Trade Secret Suit Trimmed In Ohio

    An Ohio federal judge has kept alive most of medical equipment supplier Steris' lawsuit claim that a former research and development director stole its intellectual property to form a competitor, but agreed to trim some claims in the case.

  • June 26, 2026

    DC Circ. Affirms FDA Can Block Norwich's IBS Generic

    The D.C. Circuit on Friday backed the U.S. Food and Drug Administration's lower court win in Norwich Pharmaceuticals' challenge to the agency's refusal to approve an application to bring a generic version of a prescription antibiotic for irritable bowel syndrome to market until 2029.

  • June 26, 2026

    EU Probing Sanofi For Disparaging Rival Flu Vaccine

    European enforcers are investigating whether Sanofi used a messaging campaign directed mainly at healthcare professionals in Germany and France to disparage the only rival flu vaccine recommended for vulnerable patients.

  • June 26, 2026

    DEA Will Back Cannabis' Medical Utility In Historic Hearing

    The U.S. Drug Enforcement Administration will kick off three weeks of hearings Monday on a proposal to move marijuana from Schedule I to Schedule III under the Controlled Substances Act, by presenting testimony asserting that the drug has a valid, currently accepted medical use.

  • June 26, 2026

    ITC Votes To Tee Up Duties For Korean Chemical Imports

    The U.S. International Trade Commission found Friday certain monomers and oligomers imported from South Korea that were determined to be selling at less than fair value are harming domestic producers, teeing up duties to be ordered on those goods.

  • June 26, 2026

    Taxation With Representation: Sidley, Paul Weiss, Kirkland

    In this week's Taxation With Representation, Germany's Merck KGaA acquires life sciences tools supplier Bio-Techne Corp., drugmaker AbbVie buys clinical-stage biotechnology company Apogee Therapeutics, and building materials supplier CRH acquires infrastructure products maker Arcosa Inc.

  • June 26, 2026

    REIT Execs Hid Queens Megacampus Woes, Suit Says

    A stockholder for life sciences-focused real estate investment trust Alexandria Real Estate Equities Inc. has alleged in California federal court that the REIT's top executives lied about how much money the company was making from its leased Queens megacampus in New York.

  • June 26, 2026

    Don't Miss It: Sidley, Cooley Steer Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple of weeks, and it's difficult to keep up with all the deals. Here, Law360 recaps the ones you may have missed, including transactions helmed by Sidley Austin LLP and Cooley LLP.

  • June 25, 2026

    Sandoz Still Can't Escape Generics Claims From GM, Others

    A Pennsylvania federal judge on Thursday declined to rethink her decision forcing Sandoz's Swiss parent company to face generic-drug price-fixing claims from major employers like American Airlines Inc. and General Motors LLC, saying the pharmaceutical company "has no new evidence" backing up its argument that the court lacks personal jurisdiction.

  • June 25, 2026

    Robo-Surgery Co., FTC Urge 9th Circ. To Revive Antitrust Case

    Surgical Instrument Service and the Federal Trade Commission urged the Ninth Circuit on Thursday to revive the company's case accusing Intuitive Surgical of blocking third parties from refurbishing components for its da Vinci surgery robot, saying a lower court erred in requiring the U.S. Supreme Court's Kodak factors to be proven.

  • June 25, 2026

    Meta Fails To Knock Out BIPA Voiceprint Privacy Claims

    A California federal judge has refused to let Meta Platforms Inc. escape an Illinois woman's proposed class claims that Meta collects "voiceprints" in violation of Illinois' Biometric Information Privacy Act, saying in a ruling unsealed Thursday that whether Meta obtained her voice recordings in a way capable of identifying her was still up for dispute.

  • June 25, 2026

    Texas Faces Tough Questions In Tylenol Autism Appeal

    A Texas appellate court seemed skeptical Thursday of an argument that the parent entities of the company that sells Tylenol should have to defend claims that the pain reliever causes autism, suggesting that the companies don't have enough ties to Texas.

  • June 25, 2026

    Anti-Pot Advocates Preview Arguments In DEA Hearings

    The anti-cannabis parties participating in upcoming U.S. Drug Enforcement Administration hearings on a proposal to change marijuana's Schedule I status will argue that the drug poses too many public health and safety risks for the government to loosen restrictions on it.

  • June 25, 2026

    Novo Nordisk Gets 401(k) Investment Suit Narrowed

    A New Jersey federal judge dismissed allegations accusing Novo Nordisk of unlawfully keeping underperforming investment options in its employee 401(k) plan, handing the pharmaceutical company a partial win by concluding workers hadn't identified comparable funds that performed significantly better.

  • June 25, 2026

    No Immunity In Idaho THC Child Abuse Registry Suit

    An Idaho federal judge won't throw out a class action alleging Idaho violates constitutional rights by placing women on the state's Child Protection Central Registry for using THC during pregnancy, finding the director of the state's Department of Health and Welfare doesn't have immunity against the claims.

  • June 25, 2026

    Sidley Grows In Calif. With Life Sciences, Emerging Cos. Hires

    Sidley Austin LLP announced three partner hires in California, which the firm said will enhance its capabilities in the life sciences and emerging companies and venture capital practices.

  • June 25, 2026

    4th Circ. Says Supply Co.'s Foreign Member Kills Diversity

    The Fourth Circuit on Thursday declined to reinstate a medical supply company's contract dispute against a U.K. corporation over COVID-19 test kits, after finding that the lack of a U.S. citizen on the supply company's side destroys the court's diversity jurisdiction to hear the case.  

  • June 25, 2026

    2 Firms Lead Merck's $11.3B Bio-Techne Life Sciences Deal

    Germany's Merck has agreed to acquire Bio-Techne Corp. in an all-cash deal valuing the U.S.-based life sciences tools company at about $11.3 billion, including debt, the companies said Thursday.

  • June 25, 2026

    Monsanto Wins High Court Fight Over Roundup Cancer Warnings

    The U.S. Supreme Court on Thursday handed Monsanto a win in its long-running litigation battle over the labeling of alleged cancer risks of its bestselling weedkiller Roundup, clearing the path for a $7.25 billion settlement to end thousands of suits facing the Bayer AG unit by finding that the state law claims underlying a $1.25 million jury verdict are barred.

  • June 24, 2026

    NY Judge Halts DOJ Bid For Trans Youth Medical Records

    A New York federal judge Wednesday barred the U.S. Department of Justice from seeking medical records of transgender patients who received gender-affirming care as minors in the wake of a grand jury subpoena to NYU Langone Health System, saying the government's investigation doesn't outweigh the patients' privacy interests.

Expert Analysis

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

  • 2025's Most Notable State AG Activity By The Numbers

    Author Photo

    State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.

  • Opinion

    The Case For Emulating, Not Dividing, The Ninth Circuit

    Author Photo

    Champions for improved judicial administration should reject the unfounded criticisms driving recent Senate proposals to divide the Ninth Circuit and instead seek to replicate the court's unique strengths and successes, says Ninth Circuit Judge J. Clifford Wallace.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.